CN1432393A - 一种治疗冠心病心绞痛的中药制剂及其制备方法 - Google Patents
一种治疗冠心病心绞痛的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN1432393A CN1432393A CN 03105181 CN03105181A CN1432393A CN 1432393 A CN1432393 A CN 1432393A CN 03105181 CN03105181 CN 03105181 CN 03105181 A CN03105181 A CN 03105181A CN 1432393 A CN1432393 A CN 1432393A
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- preparation
- ethanol
- angina pectoris
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 14
- 208000029078 coronary artery disease Diseases 0.000 title description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 28
- 239000007788 liquid Substances 0.000 claims abstract description 23
- 239000008187 granular material Substances 0.000 claims abstract description 10
- 239000003826 tablet Substances 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
- 239000000706 filtrate Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 14
- 241000208340 Araliaceae Species 0.000 claims description 11
- 241000218176 Corydalis Species 0.000 claims description 11
- 239000009636 Huang Qi Substances 0.000 claims description 11
- 241000180649 Panax notoginseng Species 0.000 claims description 11
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 11
- 235000008434 ginseng Nutrition 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 238000004064 recycling Methods 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 7
- 239000006188 syrup Substances 0.000 claims description 7
- 235000020357 syrup Nutrition 0.000 claims description 7
- 235000008504 concentrate Nutrition 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000002481 ethanol extraction Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 229960004793 sucrose Drugs 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 206010033557 Palpitations Diseases 0.000 abstract description 2
- 241000893536 Epimedium Species 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 22
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- -1 filtered Substances 0.000 description 5
- 230000001376 precipitating effect Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 1
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031051812A CN1182862C (zh) | 2003-03-06 | 2003-03-06 | 一种治疗冠心病心绞痛的中药制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031051812A CN1182862C (zh) | 2003-03-06 | 2003-03-06 | 一种治疗冠心病心绞痛的中药制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1432393A true CN1432393A (zh) | 2003-07-30 |
CN1182862C CN1182862C (zh) | 2005-01-05 |
Family
ID=27634063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031051812A Expired - Lifetime CN1182862C (zh) | 2003-03-06 | 2003-03-06 | 一种治疗冠心病心绞痛的中药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1182862C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1297290C (zh) * | 2005-05-23 | 2007-01-31 | 刘德胜 | 一种治疗冠心病心绞痛的药物组合物及其制备方法 |
CN101926845A (zh) * | 2010-08-10 | 2010-12-29 | 邓家刚 | 一种药物组合物在制备治疗冠心病药物中的应用 |
CN103202883A (zh) * | 2013-03-15 | 2013-07-17 | 洛阳市第一中医院 | 治疗冠心病心绞痛胶囊的组分及其制备方法 |
CN104667174A (zh) * | 2015-02-03 | 2015-06-03 | 辽宁中医药大学 | 一种治疗冠心病阳虚血瘀证的液体胶囊及其制备方法 |
-
2003
- 2003-03-06 CN CNB031051812A patent/CN1182862C/zh not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1297290C (zh) * | 2005-05-23 | 2007-01-31 | 刘德胜 | 一种治疗冠心病心绞痛的药物组合物及其制备方法 |
CN101926845A (zh) * | 2010-08-10 | 2010-12-29 | 邓家刚 | 一种药物组合物在制备治疗冠心病药物中的应用 |
CN103202883A (zh) * | 2013-03-15 | 2013-07-17 | 洛阳市第一中医院 | 治疗冠心病心绞痛胶囊的组分及其制备方法 |
CN104667174A (zh) * | 2015-02-03 | 2015-06-03 | 辽宁中医药大学 | 一种治疗冠心病阳虚血瘀证的液体胶囊及其制备方法 |
CN104667174B (zh) * | 2015-02-03 | 2018-02-06 | 辽宁中医药大学 | 一种治疗冠心病阳虚血瘀证的液体胶囊及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1182862C (zh) | 2005-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102772748B (zh) | 一种治疗肝郁气滞型病毒性心肌炎的中药制剂及其制备方法 | |
CN101524469B (zh) | 一种治疗充血性心力衰竭的中药复方制剂及其制备方法 | |
CN101011522A (zh) | 一种治疗心脏病的中药制剂 | |
CN1895547B (zh) | 一种治疗2型糖尿病的药物及制备方法 | |
CN104873705A (zh) | 一种治疗冠心病心绞痛的药物组合物及其应用 | |
CN104857154A (zh) | 一种治疗“三高”症的中药组合物及其制备方法 | |
CN102614474A (zh) | 用于治疗冠心病的中药及其制备方法 | |
CN1182862C (zh) | 一种治疗冠心病心绞痛的中药制剂及其制备方法 | |
CN102847061A (zh) | 一种治疗小儿病毒性心肌炎的中药制剂及其制备方法 | |
CN107260853B (zh) | 一种具有治疗心力衰竭作用的中药复方组合物及其制备方法与应用 | |
CN102293855A (zh) | 治疗脾肾两虚型糖尿病肾病的中药组合物及其制备方法与应用 | |
CN105012873A (zh) | 一种降血脂的月见草保健口服液及其制备方法 | |
CN1970050B (zh) | 一种治疗心率失常的药物组合物及其制备方法 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN102228596B (zh) | 一种药物组合物及制剂及在治疗冠心病、心绞痛中的应用 | |
CN1245197C (zh) | 治疗冠心病、病毒性心肌炎的中药制剂 | |
CN106620253B (zh) | 一种治疗缓慢性心律失常的中药组合物 | |
CN105126034A (zh) | 一种用于治疗冠心病的药物制剂 | |
CN104524461A (zh) | 一种治疗心肌炎的药物组合物及其应用 | |
CN104256618A (zh) | 一种降血糖的食品、保健品或药物组合物 | |
CN103393938A (zh) | 一种降血糖的中药组合物 | |
CN111514237B (zh) | 一种治疗病毒性心肌炎的中药组合物及其制备方法 | |
CN102772665B (zh) | 一种治疗阴虚内热型病毒性心肌炎的中药制剂及其制备方法 | |
CN102133332B (zh) | 一种预防和治疗冠心病与心绞痛的中药合方制剂及其制备方法 | |
CN105311425A (zh) | 含有艾叶的药物组合物用于制备治疗心肌梗死药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Ling Peixue Document name: Notification to Pay the Fees |
|
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Ling Peixue Inventor after: Zhang Ling Inventor after: Shi Yanzeng Inventor after: Shang Lixia Inventor before: Ling Peixue Inventor before: Zhang Ling Inventor before: Shi Yanzeng Inventor before: Qu Yanwei Inventor before: Shang Lixia Inventor before: Hu Qingwen |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LING PEIXUE ZHANG LING SHI YANZENG QU YANWEI SHANG LIXIA HU QINGWEN TO: LING PEIXUE ZHANG LING SHI YANZENG SHANG LIXIA |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181214 Address after: 250101 989 Xinjie street, Ji'nan high tech Zone, Shandong Patentee after: SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES Address before: 250014 No. 264 Shanda Road, Jinan City, Shandong Province Patentee before: Ling Peixue |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20050105 |